Theme: Joining Hands in the Fight against Melanoma and Carcinoma Cancer

Melanoma 2016
Past Report of Cancer Therapy 2015

Renowned Speakers

Melanoma 2016

Conference Series LLC offers all the participants across the globe to join ‘Global Summit on Melanoma & Carcinoma’ in July 14-15, 2016 at Brisbane, Australia.

Melanoma 2016 leads towards main problems and future strategies of cancer which is going to be the leading and most promising international conference. The program delivers an opportunity for participants related to Oncologists, Dermatologists, Radiologists, Skin cancer Specialists & all the entire medical team from skin cancer departments. The conference will be structured around the theme “Joining Hands in the Fight against Melanoma and Carcinoma Cancer”.

Conference Series LLC, the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe.

With participants around the world focused on learning about Melanoma and Carcinoma treatment this is your best opportunity to reach the major assemblage of participants from the Melanoma communityoncology society, and American oncology society. Conduct presentations, distribute the information, meet with recent and potential Cancer scientists, make a splash with new drug developments, and obtain name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the latest updates in Melanoma and Carcinoma are hallmarks of this Global Skin cancer conference.

Melanoma 2016 mainly focus on the Melanoma, Carcinoma, Malignant melanoma, Causes, Staging, Diagnosis, Laboratory Diagnostic Tests, ways for the Treatment, various Therapies, Biomarkers of skin cancer,  future advance research, Cancer Nanotechnology, and its case reports.

Track 1: Melanoma

Superficial spreading melanoma in which the malignant cells tend to stay within the tissue of origin, the epidermis. Lentigo maligna also known as sun-damaged skin that consists of malignant cells but does not show invasive growth. Acral lentiginous melanoma is characterised by its origin: palm, sole, or beneath the nail. It is more common on feet than on hands. Nodular melanoma is the most aggressive type of melanoma. It grows more rapidly in thickness than in diameter. Amelanotic melanoma is a skin cancer in which the cell does not make melanin. They can be pink, red, purple or normal skin colour. Melanoma develops if there is uncontrolled growth of melanocytes; these cells are responsible for pigmentation. The majority of melanomas are cutaneous which grows within the skin. Melanoma is a type of skin cancer which spreads to other places in your body.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Melanoma Conference, July 14-15, 2016 Brisbane, Australia; 10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany;  Cervical Cancer Conference, August 04-05, 2016 Manchester, UK; Oral Cancer Conference, August 15-17, 2016 Portland, Oregon, USA; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, USA, Throat Cancer Conference August 15-17, 2016 Portland, Oregon, USA, Carcinoma Conference, July 14-15, 2016 Brisbane, Australia, Mouth Cancer Conference August 15-17, 2016 Portland, Oregon, USA; 2016 Society for Melanoma Research Congress November 6–9, 2016 Boston, Massachusetts; 16th World Congress on Cancers of the Skin August 31 – September 3, 2016 Vienna, Austria ; 12th Congress of the European Association of Dermato-Oncology August 31- Sep 3, 2016 Vienna, Austria; 4th Life and Cancer Conference 20-21 April 2017, EU Parliament, Brussels, Belgium; 13th Gastric Cancer Congress 08-11 May 2019,Prague, Czech Republic; Molecular Targets and Cancer Therapeutics conference 15-19 November 2019,Miami, Florida, USA; 12th Melanoma and Other Cutaneous Malignancies February 20, 2016 Miami Beach;  Melanoma Conference 28 – 29 October 2016, Sofitel, Sydney.

Track 2Carcinoma

Basal cell carcinoma is common form of all cancers. It occurs in cells lining the deepest part of the skin's outer layer. Squamous cell carcinoma develops on the skin. Sometimes, it may spread to the lymph nodes. Adenocarcinoma is neoplastic of epithelial tissue and it has glandular origin, glandular characteristics or both. Anaplastic carcinoma arises from uncontrolled proliferation of transformed cells from epithelial origin. Adenosquamous carcinoma is a type of cancer that contains two types of cells one is squamous cells organs and other is gland-like cells. Bronchogenic carcinoma is neoplasm of the lung which arises from the epithelium of the bronchus or bronchiole. Oat-cell carcinoma is highly malignant cancer that arises within the lung. Lung Carcinoma also known as pulmonary carcinoma which is a malignant lung tumor which has uncontrolled cell growth in tissues of the lung.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Leukemia Conference, October 17-18, 2016, Italy; 12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA 13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia, 14th World Cancer Convention, November 21-23, 2016 Dubai, UAE, Bone Marrow Transplantation Conference, October 17-18, 2016,Italy; 25th EADV Congress 28 September - 2 October 2016 - Vienna, Austria; Focus on Melanoma Meeting, RCP, 21 October 2016; 13th International Congress of the Society for Melanoma Research, November 6–9 2016, Boston, Massachusetts; Innovation and Biomarkers in Cancer Drug Development (IBCD) 8-9 September, Brussels, Belgium; Gynecological Cancer Group fall meeting 23-24 September, Lausanne, Switzerland; Gastrointestinal Tract Cancer Group autumn meeting20-22 October, Warsaw, Poland; Melanoma Group meeting, 27-28 October, Lisbon, Portugal; EORTC Symposium on Multidisciplinary Quality Assurance at World Cancer Congress 2016 01 November, Paris, France;

Track 3Malignant Melanoma

Melanoma is also known as malignant melanoma which is a type of cancer that develops from the pigment-containing cells known as melanocytes. These are the cells which produces melanin which gives colour to our skin. It is a less common, but most dangerous form of skin cancer and that may originate in any part of the body which contains the skin pigment producing cells. Mostly skin cancers are caused by too much exposure to the sun’s ultraviolet rays. Nodular melanoma is aggressive form of melanoma and it grows more rapidly in thickness than in diameter which penetrates into the skin. Oral melanomas are uncommon, and, similar to their cutaneous counterparts, they may arise primarily from melanocytes in the basal layer of the squamous mucosa. Invasive melanomas are more serious, as they penetrate deeper into the skin and may have spread to other areas of the body.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany; Melanoma Conference, July 14-15, 2016 Brisbane, Australia; Cervical Cancer Conference, August 04-05, 2016 Manchester, UK; Oral Cancer Conference, August 15-17, 2016 Portland, Oregon, USA; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, USA, Throat Cancer Conference August 15-17, 2016 Portland, Oregon, USA, Carcinoma Conference, July 14-15, 2016 Brisbane, Australia, Mouth Cancer Conference August 15-17, 2016 Portland, Oregon, USA, 16th World Congress on Cancers of the Skin 31st Aug 03 Sep 2016 Vienna, Austria; Clinical Trials – In vitro Diagnostics – Data Protection 07th September Brussels, Belgium; Innovation and Biomarkers in Cancer Drug Development (IBCD) 8-9 September, Brussels, Belgium; Gynaecological Cancer Group fall meeting 23-24 September, Lausanne, Switzerland; Gastrointestinal Tract Cancer Group autumn meeting 20-22 October, Warsaw, Poland; Melanoma Group meeting, 27-28 October, Lisbon, Portugal; EORTC Symposium on Multidisciplinary Quality Assurance at World Cancer Congress 2016 01 November, Paris, France; Radiation Oncology Group meeting, 07-08 November, Berlin, Germany;

Track 4: Melanoma and Carcinoma: Cause

Melanoma is a type of cancer which develops from the pigment containing cells called melanocytes. These are the cells that produce melanin which is a pigment that gives colours to our skin. It is a less common, but most dangerous form of skin cancer. Ultraviolet rays are most common reason for skin cancers which were caused by too much exposure to the sun’s ultraviolet rays. The two types of UV rays that cause melanoma are UV-A and UV-B rays. A number of reasons often run in families, greatly increase melanoma susceptibility. Several genes increase risk of melanoma. The persons born with the giant congenital melanocytic nevi are at risk. Possible significant elements in determining risk may include the intensity and duration of sun exposure, the age at which sun exposure occurs to the person. UV radiation will cause damage to the DNA of cells.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany; Melanoma Conference, July 14-15, 2016 Brisbane, Australia; Cervical Cancer Conference, August 04-05, 2016 Manchester, UK; Oral Cancer Conference, August 15-17, 2016 Portland, Oregon, USA; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, USA, Throat Cancer Conference August 15-17, 2016 Portland, Oregon, USA, Carcinoma Conference, July 14-15, 2016 Brisbane, Australia, Mouth Cancer Conference August 15-17, 2016 Portland, Oregon, USA, 16th World Congress on Cancers of the Skin 31st Aug 03 Sep 2016 Vienna, Austria; Clinical Trials – In vitro Diagnostics – Data Protection 07th September Brussels, Belgium; Innovation and Biomarkers in Cancer Drug Development (IBCD) 8-9 September, Brussels, Belgium; Gynecological Cancer Group fall meeting 23-24 September, Lausanne, Switzerland; Gastrointestinal Tract Cancer Group autumn meeting 20-22 October, Warsaw, Poland; Melanoma Group meeting, 27-28 October, Lisbon, Portugal; EORTC Symposium on Multidisciplinary Quality Assurance at World Cancer Congress 2016 01 November, Paris, France; Radiation Oncology Group meeting, 07-08 November, Berlin, Germany;

Track 5: Melanoma Staging

The stages refers to the thickness, depth of penetration, and the degree of which melanoma has been spreaded. The staging is used to determine treatment for Melanoma. The melanoma stages can be distinguished as early melanomas (Stages 0 and I) are localized; Stage 0 tumors may be in situ also, that means they are non-invasive and not penetrated below the surface of the skin. While Stage I tumors are invaded in the skin but are small and nonulcerated, and grows at slow mitotic rate. Stage II tumors, though localized but they are larger (generally over 1 mm. thick) and may be ulcerated or have a mitotic rate which is greater than 1/mm2; they are considered as intermediate melanomas. More advanced melanomas (Stages III and IV) spread to other parts of the body. These are also subdivisions within stages.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Carcinoma Conference, July 14-15, 2016 Brisbane, Australia; 2nd  Paediatric Oncology Conference , June 22-23, 2017 Philadelphia, USA; 2nd  Prostate Cancer Conference, August 22-23, 2016 Philadelphia, Pennsylvania, USA; 10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany; Melanoma Conference, July 14-15, 2016 Brisbane, Australia;12th World Cancer ConferenceSeptember 26-28, 2016 London, UK , 12th Congress of the European Association of Dermato-Oncology August 31- Sep 3, 2016 Vienna, Austria;  25th EADV Congress 28 September - 2 October 2016 - Vienna, Austria; Focus on Melanoma Meeting, RCP, 21 October 2016; 13th International Congress of the Society for Melanoma Research, November 6–9 2016, Boston, Massachusetts; Radiation Oncology Group meeting, 07-08 November, Berlin, Germany;  4th Life and Cancer Conference 20-21 April 2017, EU Parliament, Brussels, Belgium; 13th International Gastric Cancer Congress 08-11 May 2019,Prague, Czech Republic;  Molecular Targets and Cancer Therapeutics conference 15-19 November 2019,Miami, Florida, USA; 12th International Symposium on Melanoma and Other Cutaneous Malignancies February 20, 2016 Miami Beach;

Track 6: Melanoma and Carcinoma Diagnosis

A symmetrical skin lesion to which the border of the lesion is irregular. Melanomas usually have multiple colours. Diameters of moles greater than 6 mm are more likely to be melanomas than smaller moles. A Seborrheic keratosis is a benign skin growth that originates in keratinocytes. An ugly duckling may be a single large mole which is dark in amongst a sea of smaller lighter moles, or it may be a single small light mole in amongst a sea of large dark moles. Skin biopsy is a biopsy technique in which a skin lesion is removed. Intraocular melanoma is a disease in which malignant cells forms in the tissues of the eye. The tumor microenvironment is having cellular environment in which the tumor exists, including the surrounding blood vessels, immune cells and fibroblasts. The immune cells in the microenvironment can affect the growth and evolution of cancerous cells. The environmental factors may produce more risk of carcinoma cancer.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Melanoma Conference, July 14-15, 2016 Brisbane, Australia; 10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany;  Cervical Cancer Conference, August 04-05, 2016 Manchester, UK; Oral Cancer Conference, August 15-17, 2016 Portland, Oregon, USA; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, USA, Throat Cancer Conference August 15-17, 2016 Portland, Oregon, USA, Carcinoma Conference, July 14-15, 2016 Brisbane, Australia, Mouth Cancer Conference August 15-17, 2016 Portland, Oregon, USA; 2016 Society for Melanoma Research Congress November 6–9, 2016 Boston, Massachusetts; 16th World Congress on Cancers of the Skin August 31 – September 3, 2016 Vienna, Austria ; 12th Congress of the European Association of Dermato-Oncology August 31- Sep 3, 2016 Vienna, Austria; 4th Life and Cancer Conference 20-21 April 2017, EU Parliament, Brussels, Belgium; 13th Gastric Cancer Congress 08-11 May 2019,Prague, Czech Republic; Molecular Targets and Cancer Therapeutics conference 15-19 November 2019,Miami, Florida, USA; 12th Melanoma and Other Cutaneous Malignancies February 20, 2016 Miami Beach;  Melanoma Conference 28 – 29 October 2016, Sofitel, Sydney.

Track 7: Melanoma and Carcinoma: Treatment

Surgery to remove margin of normal skin around the melanoma occurred. The amount of normal skin removed depends on the thickness and location of the melanoma occurred but not more than 2 cm (4/5 inch) and the normal skin needs to be removed from all sides of the melanoma. The wider margins make more healing and have not been found to help people live longer. If cancer cells found on the sentinel lymph node then the dissection process is recommended, but it’s not clear whether  it helpful to improve survival. Skin tumors or enlarged lymph nodes causing symptoms can be removed by surgery or they may be treated with radiation therapy. Metastases in internal organs are sometimes removed, depending on how many are there, where they are found, and how likely they are to causing symptoms. Metastases cannot be removed they are treated with radiation, immunotherapy, targeted therapy, or chemotherapy.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Melanoma Conference, July 14-15, 2016 Brisbane, Australia; 10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany;  Cervical Cancer Conference, August 04-05, 2016 Manchester, UK; Oral Cancer Conference, August 15-17, 2016 Portland, Oregon, USA; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, USA, Throat Cancer Conference August 15-17, 2016 Portland, Oregon, USA, Carcinoma Conference, July 14-15, 2016 Brisbane, Australia, Mouth Cancer Conference August 15-17, 2016 Portland, Oregon, USA; 2016 Society for Melanoma Research Congress November 6–9, 2016 Boston, Massachusetts; 16th World Congress on Cancers of the Skin August 31 – September 3, 2016 Vienna, Austria ; 12th Congress of the European Association of Dermato-Oncology August 31- Sep 3, 2016 Vienna, Austria; 4th Life and Cancer Conference 20-21 April 2017, EU Parliament, Brussels, Belgium; 13th Gastric Cancer Congress 08-11 May 2019,Prague, Czech Republic; Molecular Targets and Cancer Therapeutics conference 15-19 November 2019,Miami, Florida, USA; 12th Melanoma and Other Cutaneous Malignancies February 20, 2016 Miami Beach;  Melanoma Conference 28 – 29 October 2016, Sofitel, Sydney.

Track 8: Melanoma and Carcinoma: Therapy

Therapy for melanoma after initial treatment depends on the stage of the melanoma, what treatments that person already had, where that melanoma comes again, and other factors are considered. Melanoma and carcinoma might come again on the skin or near the site of the original tumor, sometimes even in the scar from the surgery it depends. In general case, these local recurrences are treated with surgery for a primary melanoma. Depending on the thickness and location of the melanoma tumor, therapies and other treatments may be considered, such as isolated limb perfusion chemotherapy; radiation therapy; Biological therapy; Cow’s Urine Therapy; tumor injection with BCG vaccine, interferon, or interleukin-2. There are even systemic treatments such as Retroviral mediated gene therapy; Oncolytic virotherapy; immunotherapy, chemotherapy or targeted therapy.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany; Melanoma Conference, July 14-15, 2016 Brisbane, Australia; Cervical Cancer Conference, August 04-05, 2016 Manchester, UK; Oral Cancer Conference, August 15-17, 2016 Portland, Oregon, USA; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, USA, Throat Cancer Conference August 15-17, 2016 Portland, Oregon, USA, Carcinoma Conference, July 14-15, 2016 Brisbane, Australia, Mouth Cancer Conference August 15-17, 2016 Portland, Oregon, USA, 16th World Congress on Cancers of the Skin 31st Aug 03 Sep 2016 Vienna, Austria; Clinical Trials – In vitro Diagnostics – Data Protection 07th September Brussels, Belgium; Innovation and Biomarkers in Cancer Drug Development (IBCD) 8-9 September, Brussels, Belgium; Gynecological Cancer Group fall meeting 23-24 September, Lausanne, Switzerland; Gastrointestinal Tract Cancer Group autumn meeting 20-22 October, Warsaw, Poland; Melanoma Group meeting, 27-28 October, Lisbon, Portugal; EORTC Symposium on Multidisciplinary Quality Assurance at World Cancer Congress 2016 01 November, Paris, France; Radiation Oncology Group meeting, 07-08 November, Berlin, Germany;

Track 9: Melanoma and Carcinoma: Biomarkers

A cancer biomarker refers to a substance that indicates the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor. The Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used mostly for the cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected from bio fluids like blood or serum. The ambiguous melanocytic neoplasms which are benign nevi from those that represent true melanoma for treatment and prognosis. Diagnostic biomarkers currently used to assist in the diagnosis of melanoma are usually it is only for melanocytic malignant neoplasm and not for their ability to metastasize. Traditional prognostic biomarkers include invasion and mitotic count. Newer diagnostic and prognostic biomarker utilizes immunohistochemical staining with ribonucleic acid, micro-ribonucleic acid, and deoxyribonucleic acid assays and fluorescence in situ hybridization. Improved diagnostic and prognostic biomarkers are increasing importance in the treatment of melanoma with the development of newer and more targeted therapies.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Carcinoma Conference, July 14-15, 2016 Brisbane, Australia; 2nd  Paediatric Oncology Conference , June 22-23, 2017 Philadelphia, USA; 2nd  Prostate Cancer Conference, August 22-23, 2016 Philadelphia, Pennsylvania, USA; 10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany; Melanoma Conference, July 14-15, 2016 Brisbane, Australia;12th World Cancer ConferenceSeptember 26-28, 2016 London, UK , 12th Congress of the European Association of Dermato-Oncology August 31- Sep 3, 2016 Vienna, Austria;  25th EADV Congress 28 September - 2 October 2016 - Vienna, Austria; Focus on Melanoma Meeting, RCP, 21 October 2016; 13th International Congress of the Society for Melanoma Research, November 6–9 2016, Boston, Massachusetts; Radiation Oncology Group meeting, 07-08 November, Berlin, Germany;  4th Life and Cancer Conference 20-21 April 2017, EU Parliament, Brussels, Belgium; 13th International Gastric Cancer Congress 08-11 May 2019,Prague, Czech Republic;  Molecular Targets and Cancer Therapeutics conference 15-19 November 2019,Miami, Florida, USA; 12th International Symposium on Melanoma and Other Cutaneous Malignancies February 20, 2016 Miami Beach;

Track 10: Melanoma and Carcinoma: Advance research

Advances in Cancer Research have covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. Melanoma is common type of skin cancer, but the most deadly cancer. It accounts approximately four per cent of all skin cancer cases, but 80% of skin cancer deaths. Melanoma can be challenging to diagnose and tests uses a gene to differentiate malignant melanoma from benign skin lesions. Chemoprevention refers to the use of agents to prevent carcinogenic progression of cancer. Chemoprevention is an unexplored strategy in melanoma preventionDNA vaccination with advanced malignant melanoma is an safe and potentially therapeutic. Even Though early detection, appropriate surgery, and in some cases adjuvant therapy improved outcomes for at least one third of patients with early-stage melanoma which will develop metastases. The effort to potentially maximize outcomes biochemotherapy was evaluated.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Melanoma Conference, July 14-15, 2016 Brisbane, Australia; 10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany;  Cervical Cancer Conference, August 04-05, 2016 Manchester, UK; Oral Cancer Conference, August 15-17, 2016 Portland, Oregon, USA; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, USA, Throat Cancer Conference August 15-17, 2016 Portland, Oregon, USA, Carcinoma Conference, July 14-15, 2016 Brisbane, Australia, Mouth Cancer Conference August 15-17, 2016 Portland, Oregon, USA; 2016 Society for Melanoma Research Congress November 6–9, 2016 Boston, Massachusetts; 16th World Congress on Cancers of the Skin August 31 – September 3, 2016 Vienna, Austria ; 12th Congress of the European Association of Dermato-Oncology August 31- Sep 3, 2016 Vienna, Austria; 4th Life and Cancer Conference 20-21 April 2017, EU Parliament, Brussels, Belgium; 13th Gastric Cancer Congress 08-11 May 2019,Prague, Czech Republic; Molecular Targets and Cancer Therapeutics conference 15-19 November 2019,Miami, Florida, USA; 12th Melanoma and Other Cutaneous Malignancies February 20, 2016 Miami Beach;  Melanoma Conference 28 – 29 October 2016, Sofitel, Sydney.

Track 11Oncologists

Oncology practices provides oncologists, dermatologistsradiologists, clinical oncologists and other oncology   professionals with  lot of information to enhance practice efficiency and promote a high standard  quality for the patient care. For the thyroid cancer, oesophageal oncology, uterine oncology, paediatric oncology research is basically focussed on incidence and epidemiology, diagnosis, staging, risk assessment and management of differentiated cancer.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Leukemia Conference, October 17-18, 2016, Italy; 12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA 13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia, 14th World Cancer Convention, November 21-23, 2016 Dubai, UAE, Bone Marrow Transplantation Conference, October 17-18, 2016,Italy; 25th EADV Congress 28 September - 2 October 2016 - Vienna, Austria; Focus on Melanoma Meeting, RCP, 21 October 2016; 13th International Congress of the Society for Melanoma Research, November 6–9 2016, Boston, Massachusetts; Innovation and Biomarkers in Cancer Drug Development (IBCD) 8-9 September, Brussels, Belgium; Gynecological Cancer Group fall meeting 23-24 September, Lausanne, Switzerland; Gastrointestinal Tract Cancer Group autumn meeting20-22 October, Warsaw, Poland; Melanoma Group meeting, 27-28 October, Lisbon, Portugal; EORTC Symposium on Multidisciplinary Quality Assurance at World Cancer Congress 2016 01 November, Paris, France;

Track 12: Melanoma and Carcinoma Case reports

A case for Amelanotic vulvar melanoma is presented here. The patient was 71-year-old woman complaining of vulvar itching and yellowish vaginal discharge whose it underwent a complete gynaecological evaluation during which a suspicious grey-whitish mass on her vulva was observed. The tumor which is present is a superficial ulceration and it was located in the upper half of the labia minor and the clitoris. Initially it was suspected to be as a vulvar carcinoma.  So the melanoma has the potential to metastasize any organ in the body. The patients with metastatic melanoma usually have a survival of 6-9 months. We report a complete remission in an 80-year-old patient with malignant melanoma. The patient presented with the pulmonary metastases and the history of a multiple resections for local recurrence and the in-transit metastasis. The sweat gland carcinoma is a rare tumor, representing an approximately 1% of the primary skin lesions. In an around 220 cases of sweat gland carcinoma cases has been presented over the last three decades. Then the medium age for that is 57 years, with an equal male-to-female distribution.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany; Melanoma Conference, July 14-15, 2016 Brisbane, Australia; Cervical Cancer Conference, August 04-05, 2016 Manchester, UK; Oral Cancer Conference, August 15-17, 2016 Portland, Oregon, USA; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, USA, Throat Cancer Conference August 15-17, 2016 Portland, Oregon, USA, Carcinoma Conference, July 14-15, 2016 Brisbane, Australia, Mouth Cancer Conference August 15-17, 2016 Portland, Oregon, USA, 16th World Congress on Cancers of the Skin 31st Aug 03 Sep 2016 Vienna, Austria; Clinical Trials – In vitro Diagnostics – Data Protection 07th September Brussels, Belgium; Innovation and Biomarkers in Cancer Drug Development (IBCD) 8-9 September, Brussels, Belgium; Gynecological Cancer Group fall meeting 23-24 September, Lausanne, Switzerland; Gastrointestinal Tract Cancer Group autumn meeting 20-22 October, Warsaw, Poland; Melanoma Group meeting, 27-28 October, Lisbon, Portugal; EORTC Symposium on Multidisciplinary Quality Assurance at World Cancer Congress 2016 01 November, Paris, France; Radiation Oncology Group meeting, 07-08 November, Berlin, Germany;

Track 13: Entrepreneurs Investment Meet

A key ingredient in successful entrepreneurship is self-knowledge. Melanoma 2016 aims to bring together all existing and budding bio entrepreneurs to share experiences and present new innovations and challenges in Skin cancer community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Biological science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. Although life scientists are typically the founders of biotech companies, studies have shown that the most successful high tech startups are founded by a team of two to three individuals with mixed backgrounds, substantial industry experience and a very clear market and product focus at founding. This two day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from dermatologists, radiologists, oncologists and entire medical team to signalling pathways to novel therapeutic approaches to the scientific hub. In addition to our outstanding speakers, we will also showcase short talks and poster presentations from submitted abstracts. The speakers will discuss on the Cause of the Melanoma and Carcinoma cancer its Types, Diagnosis, Treatment and Therapy, Laboratory Diagnostic Tests, Advance research for Melanoma and Carcinoma, Cancer Nanotechnology, Biomarkers of Melanoma and Carcinoma cancer. This session will include risk factors and investment opportunities for melanoma research. It also deals with Prevention, Diagnosis, Therapy and Treatment of the Skin related Cancers and its innovative techniques.

Related Melanoma ConferenceCarcinoma ConferencesSkin Cancer ConferenceCancer Conferences

Carcinoma Conference, July 14-15, 2016 Brisbane, Australia; 2nd  Paediatric Oncology Conference , June 22-23, 2017 Philadelphia, USA; 2nd  Prostate Cancer Conference, August 22-23, 2016 Philadelphia, Pennsylvania, USA; 10th Global Annual Oncologists Meeting, July 11-13, 2016 Cologne, Germany; Melanoma Conference, July 14-15, 2016 Brisbane, Australia;12th World Cancer ConferenceSeptember 26-28, 2016 London, UK , 12th Congress of the European Association of Dermato-Oncology August 31- Sep 3, 2016 Vienna, Austria;  25th EADV Congress 28 September - 2 October 2016 - Vienna, Austria; Focus on Melanoma Meeting, RCP, 21 October 2016; 13th International Congress of the Society for Melanoma Research, November 6–9 2016, Boston, Massachusetts; Radiation Oncology Group meeting, 07-08 November, Berlin, Germany;  4th Life and Cancer Conference 20-21 April 2017, EU Parliament, Brussels, Belgium; 13th International Gastric Cancer Congress 08-11 May 2019,Prague, Czech Republic;  Molecular Targets and Cancer Therapeutics conference 15-19 November 2019,Miami, Florida, USA; 12th International Symposium on Melanoma and Other Cutaneous Malignancies February 20, 2016 Miami Beach;

 

 

Global Summit on Melanoma & Carcinoma

Date: July 14-15, 2016

Venue: Brisbane, Australia

Melanoma 2016 offers to discuss and debate on various aspects of key challenges, risk factors and investment opportunities for melanoma research.  It also discuss with Prevention, Diagnosis, Therapy and Treatment of the related Skin Cancers and its innovative techniques. Melanoma 2016 is a two days program for staggering growth potential and revolutionizes Skin Cancer treatments, Melanoma cancer treatments, Carcinoma diagnosis over the next 10 years.

In 2009, the average age for melanoma of the skin diagnosis was 60.8 years.The threat of developing melanoma of the skin increases with age.At the end of 2007, it was estimated that, there were 136,016 people in Australia who were detected with melanoma of the skin in the previous 26 years, including 45,753 people analysed in the previous 5 years.Relative survival rates for melanoma of the skin are higher for women than for men in Australia. The five-year comparative survival from melanoma of the skin for 2006-2010 was 88.5 per cent for men besides 93.6 per cent for women. In 2011, there were 1,544 deaths from melanoma of the skin (1,071 men and 473 women), accounting for 3.6 per cent of totally cancer deaths in Australia.In 2014, about 14,240 Australians (8,540 men and 5700 women) are expected to be identified with melanoma of the skin.In 2020, an predictable 17,570 Australians are expected to be detected with melanoma of the skin.

OMICS International beside with its subsidiary Conference Series LLC  which is encompassed of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on various Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe.

 

Why to attend?

With participants around the world focused on learning about Melanoma and Carcinoma treatment; this is your best opportunity to reach the major assemblage of participants from the Melanoma community, oncology society, and American oncology society. Conduct presentations, distribute the information, meet with recent and potential Cancer scientists, make a splash with new drug developments, and obtain name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the latest updates in Melanoma and Carcinoma are hallmarks of this Global Skin cancer conference.

 

Target Audience

Ø  Oncologists

Ø  Dermatologists

Ø  Radiologists

Ø  Pathologists

Ø  Hematologists

Ø  Academicians

Ø  Research Scholars

Ø  Students

Ø  Hematology Associations & Societies

Ø  Business Entrepreneurs

Ø  Software Developing Companies

Ø  Medical Devices Companies

Ø  Biomedical Companies

Ø  Biotechnology Companies

Ø  Data Management Companies

 

Summary

Above the past 7 years, 151 patients with malignant melanoma and Carcinoma are treated with BCG immunotherapy which is an addition to surgical therapy. The direct injection for metastatic melanoma and Carcinoma lesions limited to skin caused in 90% regression of injected lesions and 17% regression of uninfected lesions in immune competent patients. About 25% of these patients remained free of disease for 1 to 6 years. The injections of BCG into nodules of patients with subcutaneous or visceral metastases causeda lower incidence of local control and no long period survivors. Efforts to improve the results of immunotherapy in these patients by palliative surgical resection of large metastatic lesions to lower tumor burden followed by BCG immunotherapy significantly improved the results although many patients still technologically advanced recurrent disease.

 The 10-year survival rate for patients per metastatic melanoma and Carcinoma is less than 10%. Though surgery and radiation therapy have a role in the treatment of metastatic disease, systemic therapy isprovided that treatment for most patients. Single-agent chemotherapy is well known but is associated with response rates of only 5% to 20%.  The mixtureof chemotherapy and biochemotherapy may improve objective response rates but do not extend survival andrelated with greater toxicity. Immunotherapeutic approaches are in high-dose of interleukin-2 are connected with durable responses in a small percentage of patients. Metastatic melanoma continues to beinspiring disease to treat, with an estimated 8,420 associated deaths in the United States in 2008.Further 3 decades when its initial approval by the US Food and Drug Administration (FDA) in 1975, dacarbazine continues to be standard precaution for most patients with this disease. High-dose of interleukin-2 agreed by the FDA in 1998 for metastatic melanoma, benefits a small division of patients. Efforts to improve upon the survival of patients with metastatic disease have met with failure and need for successful new therapies for metastatic melanoma and Carcinoma cannot be overstated.Probably Melanoma cancer of the skin is 32,210 (4%).

Melanoma and Carcinoma Incidence rate across the World Wide

In the world wide the estimated new melanoma and Carcinoma cancer cases for all ages. In 2012 there are 232130 for both males and females. In 2015 there are 250178 for both males and females and the Demographic Change noticed is 18048.

 

Mortality rate for Melanoma and Carcinoma across the World

In world-wide the estimated melanoma and Carcinoma death cancer cases for all ages. In 2012 there are 55488 for both males and females. In 2015 there are 60098 for both males and females and the Demographic Change noticed is 4610.

 

Melanoma and Carcinoma Incidence rate in Australia

In Australia the estimated new melanoma and Carcinoma cancer cases for all ages. In 2012 there are 12265 for both males and females. In 2015 there are 13111 for both males and females and the Demographic Change noticed is 846. 

Mortality due to Melanoma and Carcinoma across the Australia

In Australia the estimated melanoma and Carcinoma death cancer cases for all ages are: In 2012 there are 1642 for both males and females. In 2015 there are 1775 for both males and females and the Demographic change noticed is 133.

 

Melanoma and Carcinoma Conference Highlights:

Melanoma and Carcinoma Cause

Melanoma Types

Carcinoma Types

Melanoma and Carcinoma Diagnosis

Melanoma and Carcinoma Treatment and Therapy

Melanoma and Carcinoma Laboratory Diagnostic Tests

Melanoma and Carcinoma Advance research

Melanoma and Carcinoma Cancer nanotechnology

Melanoma and Carcinoma  Biomarkers

 

Scope and Importance

The Melanoma EpiCast Report brings an overview of the risk factors, comorbidities, and the global and earlier trends for melanoma of the skin in the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It involves10-year epidemiological forecast for the diagnosed incident cases of melanoma of the skin, segmented by age, sex, and cancer growthperiod at diagnosis (American Joint Commission on Cancer [AJCC] stages I, II, III, and IV). The estimation also includes a 10-year epidemiological calculation for the five-year diagnosed predominant cases and the five-year diagnosed prevalent cases segmented by genetic aberrations (BRAF and c-KIT) in these markets.

The melanoma epidemiology explosion is written and developed by Mastersand PhD-level epidemiologists.The Epicast Report is thorough, high quality, transparent and market-driven, provided that expert analysis of disease trends in the eight major markets.

 

Why it’s in Brisbane Australia?

Brisbane has gained the exactly 1,500 of the world’s leading Melanoma and skin cancer specialists. Queensland has the exciting incidence of skin cancer in the world. Every year skin cancers report for 80% of all newly analysed cancers, with medical practitioners given that more than one million patient consultations resulting in a significant burden on the state’s health care system.Now the 9th World Congress of Melanoma held at the Brisbane Convention & Exhibition Centre (BCEC)in October 2017, given a certain global platform for the world’s foremostscholars, skin cancer specialists and medical professionals.Sight-seeing and Events of Queensland and Brisbane Marketing also played a significant roles in securing the four day conference for Brisbane.Success in securing the return of the Congress to Australian shores for just the second time in 20 years is testimony to Brisbane’s world class research reputation and active engagement in the area of Melanoma and Melanoma management and will provide an opportunity to showcase the ground breaking work of Queensland based researchers and clinicians.

   Brisbane and Australia are well recognised as world leaders in this area, developing new frontiers in research in skin cancer, its origins and treatment. Queensland has the highest rate of skin cancer in the world and Australia overall has two to three times the rates experienced in Canada, the United States and the United Kingdom. We welcome the opportunity to host this important event to share expertise and drive greater action on local and global skin control Brisbane’s reputation and track record for hosting major international events and its appeal to the international scientific and research sectors.“These events have enormous benefit for Brisbane in financial terms, but also in fostering international collaboration, driving investment and delivering research outcomes.“Brisbane is already recognised as an Asia Pacific conventions hotspot, and that reputation will only grow as the city gears up for the G20 World Leaders Summit in November 2014.

      Brisbane will also play host to cancer experts from around the world this November (21-24) at the first ever global skin cancer conference hosted by Cancer Council Queensland. Global Controversies and Advances in Skin Cancer to be held at the BCEC will provide a forum for international, cutting edge debate across prevention, diagnosis, treatment, management and survivorship for all types of skin cancer.

 

Why to Attend?

Informative public with recent advances in Melanoma Cancer diagnosis and therapy from around the world focused on cancer about recent advances in Melanoma Cancer diagnosis and therapy, this is your single best opportunity to reach the largest assemblage of participants .World-renowned speakers, the most recent techniques, and the newest updates in Melanoma Cancer research fields are hallmarks of this conference.

 

Members Associated with Melanoma and Carcinoma Research

In Melanoma and Carcinoma research the members associated are in Worldwide 965 members associated. In Australia 362 members are associated. In Brisbane 143 members are associated.

 

·         Reg Richardson - AM FCPA FCIS ACSA Dip CM (Chairman | MIA)

·         Natalie Foster( Surgical Oncology)

·         Professor Helen Rizos - BSc (Hon) PhD

·         Jennifer Elliott - BA, LLB (Hons), MA, FAICD( Acting General Manager)

·         Garry Sladden - BBus CPA FINSA

·      Helen Schmid - RN, RM, DipAppSc, DipMgt, MPH (Project and Business Manager, Cancer Genetic Epidemiology)

·         Dr Sarah-Jane Schramm – PhD

·         Professor John Thompson - AO MBBS BSc(Med) MD FRACS FACS (Executive Director | MIA)

·         Associate Professor Jonathan Stretch - AM D.Phil (Oxon) FRACS (Deputy Director | MIA)

·         Dr Hamideh Shahheydari – PhD (Postdoctoral Fellow)

·         Professor Fran Boyle - AM MBBS (QLD) FRACP PhD

·         Professor Richard Kefford - AM MB BS PhD FRACP

·         Dr Matteo Carlino - BMedSc, MBBS, FRACP

·         Lydia Visintin - R.N, MCaHaemN (Clinical Nurse Consultant)

·         Associate Professor Georgina Long - BSc PhD MBBS FRACP

·         Gayathri St. George - Bmed.Sc, MSc.Med (RHHG) (PhD candidate)

·         Mitchell Stark - BAppSc(hons)

·         Professor Omgo E. Nieweg - MD, PhD

·         Caroline Watts - RN, RM, BA (Hons), MPH (Project Manager, Melanoma Registrar)

·         Associate Professor Sydney Ch’ing - MBBS, PhD, FRACS

·         Dr Robyn Saw - MBBS, FRACS, MS

·         Dr Sarah Welsh - BSc PhD MBChB MRCP (Medical Oncology)

·         Judith Symmons – RN (Research Nurse)

·         Professor Richard Scolyer - BMedSci, MBBS

·         Dr James WIlmott – BSc (Hons) PhD (Postdoctoral Researcher)

·         Dr Kerwin Shannon (Surgeon)

·         Dr Gerald Fogarty - BSc, MBBS, FRANZCR

·         Dr Angela Hong - MBBS MMed FRANZCR PhD

·         Dr Lauren Aoude – PhD

·         Varsha Tembe – PhD

·         Dr Farad (Fred) Azimi - BSc (Med), MBBS, Masters of Surgery

·         Dr Heidi Cameron - MBBS, FRACS

·         Dr Annette Chakera - MD, PhD

·         Dr Anne Cust - PhD, MPH(Hons), BSc, BA

·         Professor Diona Damian – PhD

·         Melanie Doyle – RN

·         Libby Emmett - RN, Onc Cert, MMedSc

·         Dr Stuart Gallagher – PhD

·         Maria Gonzalez - BN BA M.Hlth.Sc

·         Danielle Gibbs (Research Assistant)

·         Dr Kavitha Gowrishankar – PhD

·         Associate Professor Pascale Guitera - FACD PhD

·         Professor Nick Hayward – PhD

·         Professor Peter Hersey - MBBS, FRACP, D.Phil (Oxon)

·         Anna Hoadley - BA, MNurs, Grad Cert (Oncology)

·         Elizabeth Holland - BSc Macquarie University

·         Dr Lodewijka Holtkamp – MD PhD Student

·         Associate Professor T. Michael Hughes - MBBS (Hons I) Sydney, FRACS

·         Dr Peter Johansson – PhD

·         Dr Teresa Lee – PhD

·         Dr Serigne Lo – PhD Senior Statistician, Senior Research Fellow - University of Sydney

·         Professor Graham Mann – PhD

·         Dr Linda Martin - BSc(Med) MBBS(Hons) MMed FACD

·         Professor William McCarthy – AM

·         Dr Catriona McNeil - MBBS BSc(Med) PhD FRACP

·         Dr Alex Menzies - BSc(Med) MBBS (Hons) FRACP

 

 

Hospitals Associated with Melanoma and Carcinoma Research

In Melanoma and Carcinoma research the hospitals associated in Worldwide 720 hospitals are associated. In Australia 492 hospitals are associated. In Brisbane 105 hospitals are associated.

 

Melanoma Research Foundation

Royal Prince Alfred Hospital

Royal Adelaide Hospital

Community Hospitals

UH Ahuja Medical Center

Calvary Health Care Tasmania St John's Campus

Clare Holland House

Mater Hospital

Melanoma International Foundation

Canberra Hospital, Canberra

National Capital Private Hospital

Canberra Eye Hospital

Gold Coast University Hospital

Major Associations for Melanoma and Carcinoma Cancer

In Melanoma and Carcinoma research the Societies associated in Worldwide 395 societies are associated. In Australia 55 societies are associated. In Brisbane 11 societies are associated.

Worldwide Cancer Research Society

  • American Cancer Society

  • Avon Foundation for Women

  • Cancer Research Institute

  • Conquer Cancer Foundation

  • Damon Runyon Cancer Research Foundation

  • The V Foundation for Cancer Research

  • Society for Melanoma Research

  • International Melanoma Working Group

  • BC Cancer Foundation

 

Industries Associated with Melanoma and Carcinoma Research

In Melanoma and Carcinoma research the industries in Worldwide 172 industries are associated. In Australia 19 industries are associated. In Brisbane 5 industries are associated.

  • Roche

  • Pfizer

  • Merck & Co

  • Novartis

  • Bayer

  • GSK

  • Astra Zeneca

  • Avastin

  • Abbott

  • Lilly

  • Takeda

  • Johnson & Johnson

  • Celgene

 

Universities Associated in Melanoma and Carcinoma  Research

In Melanoma and Carcinoma research the Universities associated are in Worldwide 500 Universities are associated. In Australia 36 Universities are associated. In Brisbane 11 universities are associated

  • Melanoma Institute of Australia

  • Australian National University Medical School

  • Macquarie University Australian School of Advanced Medicine

  • Sydney Medical School

  • University of New South Wales Faculty of Medicine

  • Griffith University School of Medicine

  • Bond University Faculty of Health Sciences and Medicine

  • Deakin University

  • University of western Sydney

  • University of Melbourne

  • University of Tasmania

  • Murdoch University

Market Value for Melanoma and Carcinoma Research

The market value of melanoma and Carcinoma research at 2013 is 1.3 billion dollars, in the upcoming ten years the market value may expect to increase 5.64 billion dollars.

 

Market Growth for Melanoma and Carcinoma Research in the last and upcoming ten years

The market growth of melanoma and Carcinoma shows both increase and decrease in the last ten years and also may expected that may increase or decrease in the upcoming ten years in billion dollars.

 

Products of Melanoma and Carcinoma Cancer Market value

The melanoma and Carcinoma products and the product market is mention based on the melanoma and Carcinoma research.

Tafinlar has the market value 17,956 billion dollars in 2014

Mekinist has the market value of 10,707 billion dollars in 2014-2015

 Zelboraf has the market value of 11,076 billion dollars in 2013-2014

Proleukin has the market value of 2,530 billion dollars in 2013-2014

Opdivo has the market value of 2,454 billion dollars in 2015

Amount Funded Research for Melanoma and Carcinoma

For Melanoma and Carcinoma Research Fund Allotment is 33742250

 

Physicians, Researchers and Academicians working on Melanoma and Carcinoma

Globally there are 720 physicians, 995 researchers and 1250 academicians working on Melanoma and Carcinoma .

 

 

 

Cancer Summit 2015

OMICS Group’s 5th Asia-Pacific Summit on Cancer Therapy at Park Regis Brisbane, Australia during July 20-22, 2015 was organized with a focus on "Forum for a world without cancer was a great success where eminent keynote speakers from various reputed institutions made their resplendent presence and addressed the gathering.

Cancer Summit-2015 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of cancer.

Cancer Summit-2015 Organizing Committee would like to thank the Moderator of the conference, Dr. Rupinder Kaur Kanwar, Deakin University, K who contributed a lot for the smooth functioning of this event.

OMICS Group International would like to convey a warm gratitude to all the Honourable guests and Keynote Speakers of Cancer Summit-2015:

Jagat R Kanwar, Deakin University, Australia

Kwok-nam Leung, Chinese University of Hong Kong, Hong Kong

Izhak Haviv, Bar Ilan University, Israel

Pascal H G Dujif, University of Queensland, Australia

Veronica J James, Australian National University, Australia

OMICS Group, on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors. We would like to thank the Poster Competition Judge Dr. Izhak Haviv, Bar Ilan University, Israel for his valuable time.

Best Poster Winners:

OMICS Group also took the privilege of felicitating Cancer Summit-2015 Organizing Committee, Editorial Board Members of Journals of Cancer Science & TherapyJournal of Carcinogenesis & Mutagenesis and Journal of Integrative Oncology, Keynote Speakers, Chair and Co-Chairs and Moderator whose support made conference a great success.

With the enormous feedback from the participants and supporters of Cancer Summit-2015, OMICS Group Conferences is glad to announce.


Past Reports  Proceedings  Gallery  

Cancer Science-2014

OMICS International hosted 4th World Congress on Cancer Therapy during October 20-22, 2014 at Park Regis Chicago, USA with the theme “Enhanced diagnosis, treatment and management of different cancers". The conference had multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from various scientists, researchers, students and leaders from the field of oncology who made this event successful.

The conference was initiated with a series of lectures delivered by both Honourable Guests and members of the Keynote forum. The list includes:

Jeffrey B Ulmer, University of Regina, Canada.

Dr. Sudhakar Akul Yakkanti, Stanford Research Institute (SRI) International, Menlo Park California.

Reza Hakkak Professor of Pediatrics in the College of Medicine, Texas, USA

OMICS International thank all our expert presenters from all around the world which includes various outside experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.

Best poster winners:

OMICS Group also took the privilege of felicitating Cancer Science-2014 Organizing Committee, Editorial Board Members of Journals of Cancer Science & TherapyJournal of Carcinogenesis & Mutagenesis and Journal of Integrative Oncology, Keynote Speakers, Chair and Co-Chairs and Moderator whose support made conference a great success.

With the enormous feedback from the participants and supporters of Cancer Science-2014, OMICS Group Conferences is glad to announce.


Past Reports  Gallery  

Cancer Science-2013

The 3rd World Congress on Cancer Science & Therapy was organized by OMICS International during October 21-23, 2013 at Double Tree by Hilton Hotel San Francisco Airport, USA. The conference was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who have driven this event into the path of success.

The conference had multiple sessions, Keynote presentations, panel discussions and Poster sessions. Dr. Jimmy T. Efird, Brody School of Medicine, USA Was honourable Moderator for the conference.

The conference proceedings were carried out through various Keynote-presentations by:

Dr. Stewart Sell, Wadsworth Center, USA

Dr. Michael Retsky, Harvard School of Public Health, USA

Dr. Jimmy T. Efird, Brody School of Medicine, USA and the wonderful workshop session was organized by Dr. Dorothee Herlyn, The Wistar Institute, and USA.

OMICS International thank all our expert presenters from all around the world which includes various outside experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.

Best poster winners:

OMICS Group also took the privilege of felicitating Cancer Science-2013 Organizing Committee, Editorial Board Members of Journals of Cancer Science & TherapyJournal of Carcinogenesis & Mutagenesis and Journal of Integrative Oncology, Keynote Speakers, Chair and Co-Chairs and Moderator whose support made conference a great success.

With the enormous feedback from the participants and supporters of Cancer Science-2014, OMICS Group Conferences is glad to announce.

 


Past Reports  Gallery  

Cancer Science-2012

OMICS International 2nd World Congress on Cancer Science & Therapy was held during September 10-12, 2012 at Hilton San Antonio Airport, San Antonio, USA.

The conference proceedings were carried out through effectual keynote lectures by:

Dr. Sudhakar Akul Yakkanti, Boys Town National Research Hospital, USA,

Dr. Alexei G. Basnakian, University of Arkansas for Medical Sciences, USA,

Dr. Dan Dixon, University of South Carolina, USA,

Dr. Sophia Ran, Southern Illinois University School of Medicine, USA

Dr. Homer S Black, Baylor College of Medicine,USA.

OMICS International thank all our expert presenters from all around the world which includes various outside experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.

Best poster winners:

OMICS Group also took the privilege of felicitating Cancer Science-2012 Organizing Committee, Editorial Board Members of Journals of Cancer Science & TherapyJournal of Carcinogenesis & Mutagenesis and Journal of Integrative Oncology, Keynote Speakers, Chair and Co-Chairs and Moderator whose support made conference a great success.

We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Cancer Science-2012 with the unique feedback from the conference.


 

 


Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date July 14-15, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2
Poster Opportunity Available

Media Partners

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
melanoma@omicsgroup.com
Sponsors / Exhibiting / Advertising.
melanoma@conferenceseries.com
General Queries.
melanoma@conferenceseries.net

View Proceedings of Previous Conferences

Indo Cancer Summit-2015
Euro Cancer Summit - 2015
 Asia Pacific Cancer Therapy-2015
 World Cancer Therapy-2015
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.